Prot #CTT116855: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all ad

Project: Research project

StatusActive
Effective start/end date12/22/145/22/20

Funding

  • GlaxoSmithKline LLC (Prot #CTT116855)